Blood substitutes based on nanobiotechnology

Trends in Biotechnology

Volumn 24, Issue 8, 2006, Pages 372-377

  Chang, Thomas Ming Swi ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL ENGINEERING; BIOTECHNOLOGY; NANOTECHNOLOGY; SOCIETIES AND INSTITUTIONS;

CLINICAL TRIALS; COMMERCIAL ENTERPRISES; INFECTIVE AGENTS; NANOBIOTECHNOLOGY;

BLOOD SUBSTITUTES;

BLOOD SUBSTITUTE; COPOLYMER; HEMOGLOBIN DERIVATIVE; MONOPHENOL MONOOXYGENASE; POLYETHYLENE GLYCOL HEMOGLOBIN; POLYHEMOGLOBIN; POLYHEMOGLOBIN SUPEROXIDE DISMUTASE CATALASE CONJUGATE; POLYHEMOGLOBIN TYROSINASE; PROTEIN SUBUNIT; RECOMBINANT HEMOGLOBIN; UNCLASSIFIED DRUG;

BIOTECHNOLOGY; BRAIN TUMOR; CANCER CHEMOTHERAPY; CELL MATURATION; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; GLIOSARCOMA; HEMORRHAGIC SHOCK; HUMAN; LIPID MEMBRANE; LIPID VESICLE; NANOTECHNOLOGY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE;

ANIMALS; BIOMIMETIC MATERIALS; BIOTECHNOLOGY; BLOOD SUBSTITUTES; HUMANS; NANOTECHNOLOGY;

EID: 33745926240     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2006.06.005     Document Type: Review

References (45)

1. Perutz M.F. Myoglobin and Hb: role of distal residues in reactions with haem ligands. Trends Biochem. Sci. 14 (1989) 42-44
2. Chang T.M.S. Semipermeable microcapsules. Science 146 (1964) 524
3. Chang T.M.S. Stabilization of enzyme by microencapsulation with a concentrated protein solution or by crosslinking with glutaraldehyde. Biochem. Biophys. Res. Commun. 44 (1971) 1531-1533
4. Gould S.A., et al. The clinical development of human polymerized Hb. In: Chang T.M.S. (Ed). Blood Substitutes: Principles, Methods, Products and Clinical Trials Vol. 2 (1998), Karger, Basel 12-28
5. Gould S.A., et al. The life-sustaining capacity of human polymerized Hb when red cells might be unavailable. J. Am. Coll. Surg. 195 (2002) 445-452
6. Pearce L.B., et al. HBOC-201 (Hb glutamer-250 (bovine), hemopure): clinical studies. In: Winslow R. (Ed). Blood Substitutes (2006), Academic Press 437-450
7. Sprung J., et al. The use of bovine Hb glutamer-250 (hemopure) in surgical patients: results of a multicenter, randomized, single-blinded trial. Anesth. Analg. 94 (2002) 799-808
8. Lok C. Blood product from cattle wins approval for use in humans. Nature 410 (2001) 855
9. Li T., et al. A method for purification and viral inactivation of human placenta Hb. Artif. Cells Blood Substitutes Immobilization Biotechnol. 34 (2006) 175-188
10. Freytag J.W., and Templeton D. Optro™ (recombinant human Hb): a therapeutic for the delivery of oxygen and the restoration of blood volume in the treatment of acute blood loss in trauma and surgery. In: Rudolph A.S. (Ed). Red Cell Substitutes; Basic Principles and Clinical Application (1997), Marcel Dekker 325-334
11. Doherty D.H., et al. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free Hb. Nat. Biotechnol. 16 (1998) 672-676
12. Olsen J.S., et al. Nitric oxide scavenging and the hypertensive effect of Hb-based blood substitutes. Free Radic. Biol. Med. 36 (2004) 685-697
13. Fronticelli C., et al. Approach to the engineering of hemoglobin based oxygen carrier. Transfus. Alter. Transfus. Med. 5 (2004) 516-520
14. Klein H.G. The prospects for red-cell substitutes. N. Engl. J. Med. 342 (2000) 1666-1668
15. Winslow R. Current status of blood substitute research: towards a new paradigm. J. Intern. Med. 253 (2003) 508-517
16. Chang T.M.S. Therapeutic applications of polymeric artificial cells. Nat. Rev. Drug Discov. 4 (2005) 221-235
17. In: Winslow R. (Ed). Blood Substitutes (2006), Academic Press
18. Chang T.M.S. Artificial Cells (1972), Charles C Thomas, Springwood, IL. http://www.artcell.mcgill.ca
19. In: Chang T.M.S. (Ed). Blood Substitutes: Principles, Methods, Products and Clinical Trials Vol.1 (1997), Karger, Basel
20. In: Kobayashi K., and Tsuchida T. (Eds). Artificial Oxygen Carriers (2005), Springer
21. Chang T.M.S. Artificial cells bioencapsulation in macro, micro, nano and molecular dimensions. Artif. Cells Blood Substitutes Immobilization Biotechnol. 32 (2004) 1-23
22. Nelson D.J. Blood and HemAssist™ (DCLHb): potentially a complementary therapeutic team. In: Chang T.M.S. (Ed). Blood Substitutes: Principles, Methods, Products and Clinical Trials Vol. 2 (1998), Karger, Basel 39-57
23. Burhop K.E., and Estep T.E. Hb induced myocardial lesions. Artif. Cells Blood Substitutes Immobilization Biotechnol. 29 (2001) 101-106
24. Yu B.L., et al. PolyHb with different percentage of tetrameric Hb and effects on vasoactivity and electrocardiogram. Artif. Cells Blood Substitutes Immobilization Biotechnol. 34 (2006) 159-175
25. Matheson B., et al. Vascular responses to infusions of a non-extravasating Hb polymer. J. Appl. Physiol. 93 (2002) 1479-1486
26. Li X., et al. Determination of the molecular weight distribution of the PEGylated bovine Hb (PEG-bHb). Artif. Cells Blood Substitutes Immobilization Biotechnol. 33 (2005) 13-28
27. Chang T.M.S. New generations of red blood cell substitutes. J. Intern. Med. 253 (2003) 527-535
28. Alayash A.I. Oxygen therapeutics: can we tame Hb. Nat. Rev. Drug Discov. 3 (2004) 152-159
29. D'Agnillo F., and Chang T.M.S. PolyHb-superoxide dismutase. catalase as a blood substitute with antioxidant properties. Nat. Biotechnol. 16 (1998) 667-671
30. Chang T.M.S., et al. A second generation Hb based blood substitute with antioxidant activities. In: Chang T.M.S. (Ed). Blood Substitutes: Principles, Methods, Products and Clinical Trials Vol. 2 (1998), Karger, Basel 178-186
31. Powanda D., and Chang T.M.S. Cross-linked PolyHb-superoxide dismutase-catalase supplies oxygen without causing blood brain barrier disruption or brain edema in a rat model of transient global brain ischemia-reperfusion. Artif. Cells Blood Substitutes Immobilization Biotechnol. 30 (2002) 25-42
32. Buehler P.W., et al. Resuscitative effects of polynitroxylated α-α-cross-linked Hb following severe hemorrhage in the rat. Free Radic. Biol. Med. 29 (2000) 764-774
33. Shorr R.G., et al. Phase 1B safety evaluation of PEG Hb as an adjuvant to radiation therapy in human cancer patients. Artif. Cells Blood Substitutes Immobilization Biotechnol. 24 (1996) 407
34. Yu B.L., and Chang T.M.S. In vitro and in vivo enzyme studies of PolyHb-tyrosinase. Biotechnol. Bioeng. 32 (2004) 311-320
35. Yu B., and Chang T.M.S. In vitro and in vivo effects of PolyHb-tyrosinase on murine B16F10 melanoma. Melanoma Res. 14 (2004) 197-202
36. Yu B.L., and Chang T.M.S. Effects of combined oral administration and intravenous injection on maintaining decreased systemic tyrosine levels in rats. Artif. Cells Blood Substitutes Immobilization Biotechnol. 32 (2004) 129-148
37. Chang T.M.S., and Poznansky M.J. Semipermeable microcapsules containing catalase for enzyme replacement in acatalasemic mice. Nature 218 (1968) 242-245
38. Djordjevich L., and Miller I.F. Synthetic erythrocytes from lipid encapsulated Hb. Exp. Hematol. 8 (1980) 584-592
39. Philips W.T., et al. Polyethylene glyco-modified liposome-encapsulated Hb: a long circulating red cell substitute. J. Pharm. Exp. Therapeutics 288 (1999) 665-670
40. Sakai H., et al. Characteristics of bovine Hb as a potential source of Hb vesicles for an artificial oxygen carrier. J. Biochem. 131 (2002) 611-617
41. Tsuchida E., et al. Preservation stability and in vivo administration of albumin-heme hybrid solution as an entirely synthetic oxygen-carrier. Polymer Adv. Technol. 13 (2002) 845-850
42. Chang T.M.S. Biodegradable semipermeable microcapsules containing enzymes, hormones, vaccines, and other biologicals. J. Bioeng. 1 (1976) 25-32
43. Yu W.P., and Chang T.M.S. Submicron polymer membrane Hb nanocapsules as potential blood substitutes: preparation and characterization. Artif. Cells Blood Substitutes Immobilization Biotechnol. 24 (1996) 169-184
44. Chang T.M.S., and Yu W.P. Nanoencapsulation of Hb and rbc enzymes based on nanotechnology and biodegradable polymer. In: Chang T.M.S. (Ed). Blood Substitutes: Principles, Methods, Products and Clinical Trials Vol.2 (1998), Karger, Basel 216-231
45. Chang T.M.S., et al. Ultrathin polyethylene-glycol-polylactide copolymer membrane nanocapsules containing polymerized Hb and enzymes as nano-dimension red blood cell substitutes. Artif. Cells Blood Substitutes Immobilization Biotechnol. 31 (2003) 231-248